Incidence, prevalence, and outcomes of systemic malignancy with bone metastases
Incidence, prevalence, and outcomes of systemic malignancy with bone metastases
复制标题
DOI：
10.1177/2309499020915989
复制
发表时间：
2020-05-01
影响因子：
1.6
通讯作者：
Liu, Jun
中科院分区：
文献类型：
--
作者：
Jiang, Wenli;Rixiati, Youlutuziayi;Liu, Jun
目的：关于全身恶性肿瘤患者骨转移的发生率、患病率和预后的证据有限。这项研究旨在利用监测、流行病学和最终结果(SEER)数据库对其进行评估。方法：我们收集了SEER数据库(2010年至2013年)诊断为骨外实体恶性肿瘤、血液恶性肿瘤、卡波西肉瘤、淋巴瘤和骨髓瘤的患者。然后分析这些伴有骨转移的系统性恶性肿瘤的发生率、患病率和预后。结果：共有67,605名癌症确诊时有骨转移的患者纳入研究。在小细胞肺癌患者中，骨转移率最高的是在替代原发部位癌症诊断的时候。在226,816例转移性疾病患者中，乳腺癌(65.58%)和前列腺癌(89.60%)的骨转移发生率较高(10%)。前列腺癌、乳腺癌和睾丸癌导致额外骨转移的患者的生存时间最长。结论：不同原发恶性肿瘤部位的骨转移瘤的发病率和预后有很大差异。这些结果可能会鼓励适当的骨显像应用。
Purpose: Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We collected patients diagnosed with solid malignant tumors deriving outside of the bone, hematologic malignancies, Kaposi sarcoma, lymphoma, and myeloma from the SEER database (from 2010 to 2013). The incidence, prevalence, and outcomes of these systemic malignancies with bone metastases were then analyzed. Results: A total of 67,605 patients with bone metastases at cancer diagnosis were included. The highest rate of bone metastases was observed in patients with small-cell lung cancer at the time of alternative primary site cancer diagnosis. Among 226,816 cases with metastatic disease, cases with breast cancer (65.58%), and prostate cancer (89.60%) had a high incidence proportion (>10%) of identified bone metastases. Patients with additional bone metastases resulting from prostate cancer, breast cancer, and testis cancer presented the best survival time. Conclusions: Incidence and prognosis differ considerably among bone metastases with different primary malignancy sites. These results may encourage appropriate application of bone imaging.